103

Reference

1. Zubay, G. L., Biochemistry; 4Ed, Worthington, R., Ed.:McGraw-Hill

Companies, Inc.: Dubuque, 1998.

2. Dugas, H., Bioorganic Chemistry; Cantor, C. R., Ed.; Springer: New York,

1996.

3. Gaál, J.; Hermecz, I., Inhibitors of Monoamine Oxidase B: Pharmaclogy

and Clinical Use in Neurodegenerative Disorders; Szelenyi, I., Ed.: Birkhauser:

Boston; Berlin, 1993.

4. Silverman, R. B., Mechanism-based enzyme inactivators. Methods in

Enzymol. 1995, 249, 240.

5. Silverman, R. B., Radical Ideas about Monoamine Oxidase. Acc Chem Res

1995, 28, 335.

6. Shaoyong Ke; Zhong Li; Xuhong Qian., 1,3,4-Oxadiazole-3(2H)-

carboxamide derivatives as potential novel class of monoamine oxidase (MAO)

inhibitors: Synthesis, evaluation, and role of urea moiety. Bioorg Med Chem

2008, 16, 7565-7572.

104

7. Kalgutkar, A. S.; Dalvie, D. K.; Castagnoli, N., Jr.; Taylor, T., Chem Res

Toxicol 2001, 14, 1139-1162.

8. Haung, R. H.; Faulkner, R. The role of phospholipid in the multiple

functional forms of brain monoamine oxidase. J Biol Chem 1981, 256, 9211-

9215.

9. Cohen, G.; Farooqui, R.; Kesler, N., Parkinson disease: A new link

between monoamine oxidase and mitochondrial electron flow. Proc Natl Acad

Sci U.S.A. 1997, 94, 4890-4894.

10. Edmondson, D. E.; Mattevi, A.; Binda, C.; Li, M.; Hubálek, F., Structure

and Mechanism of Monoamine Oxidase. Curr Med Chem 2004, 11, 1983-1993.

11. Youdim, M. B. H.; Finberg, J. P. M., New directions in monoamine

oxidase A and B selective inhibitors and substrates. Biochem Pharmacol 1991,

41, 155-162.

12. Gottowik, J.; Cesura, A. M.; Malherbe, P.; Lang, G.; Prada, M. D.,

Characterisation of wild-type and mutant forms of human monoamine oxidase

A and B expressed in a mammalian cell line. FEBS Lett 1993, 317, 152-156.

105

13. Geha, R. M.; Rebrin, I.; Chen, K.; Shih, J. C., Substrate and inhibitor

specificities for human monoamine oxidase A and B are influenced by a single

amino acid. J Biol Chem 2001, 276, 9877-9882.

14. Westlund, K. N.; Denney, R. M.; Kochersperger, L. M.; Rose, R. M.; Abell,

C. W., Distinct monoamine oxidase A and B populations in primate brain.

Science 1985, 230, 181-183.

15. Bach, A. W. J.; Lan, N. C.; Johnson, D. L.; Abell, C. W.; Bembenek, M.

E.; Kwan, S.W.; Seeburg, P. H.; Shih, J. C., cDNA cloning of human liver

monoamine oxidase A and B: molecular basis of differences in enzymatic

properties. Proc Natl Acad Sci U.S.A. 1988, 85, 4934-4938.

16. Grimsby, J.; Chen, K.; Wang, L. J.; Lan, N. C.; Shin, J. C., Human

monoamine oxidase A and B genes exhibit identical exon-intron organization.

Proc Natl Acad Sci U.S.A. 1991, 88, 3637-3641.

17. Binda, C.; Newton-Vinson, P.; Hubálek, F.; Edmondson, DE.; Mattevi, A.,

Structure of human monoamine oxidase B, a drug target for the treatment of

neurological disorders. Nat Struct Biol 2002, 9, 22-26.

106

18. Youdim, M.B.H.; Finberg, J.P.M.; Tipton, K.F., Monoamine oxidase. In:

Advances in Experimental Pharmacology. Catecholamine. II. ed. Trendelenburg,

U. & Weiner, U., Berlin: Springer-Verlag. 1988, 119-192.

19. Finberg, J.P.; Tenne, M., selective inhibition of monoamine oxidase types

A and B in the rat vas deferens. Br J Pharmacol 1982, 77, 13-21.

20. Finberg, J.P.; Tenne, M.; Youdim, M.B., Tyramine antagonistic properties

of AGN 1135, an irreversible inhibitor of monoamine oxidase type B. Br J

Pharmacol 1981, 73, 65-74.

21. Birkmayer, W.; Knoll, J.; Riederer, P.; Youdim, M.B.; Hars, V.; Marton,

J., Increased life expectancy resulting from addition of L-deprenyl to Madopar

treatment in Parkinson's disease: a longterm study. J Neural Transm 1985, 64,

113-127.

22. De Colibus, L.; Li, M.; Binda, C.; Lustig, A.; Edmondson, DE.; Mattevi,

A., Three-dimensional structure of human monoamine oxidase A (MAO A):

relation to the structures of rat MAO A and human MAO B. Proc Natl Acad Sci

U.S.A 2005, 102, 12684-12689.

23. Binda, C.; Mattevi, A.; Edmondson, D E., Structure-function

relationships in flavoenzyme-dependent amine oxidations: a comparison of

107

polyamine oxidase and monoamine oxidase. J Biol Chem 2002, 277, 23973-

23976.

24. National Institute of Neurological disorders and Stroke NIH Institute,

Parkinson's Disease: Hope Through Research, 2008.

25. Magyar, K.; Pálfi, M.; Tábi, T.; Kalász, H.; Szende, B.; Szöko, E.,

Pharmacological aspects of (-)-deprenyl. Curr Med Chem 2004, 11, 2017-2031.

26. Baumgarten, H.G.; Zimmermann, G., In Handbook of Exp. Pharm.,

Springer-Verlag, 1992.

27. Langston, J.W.; Ballard, P.; Tetrud, J.W.; Irwin, I., Chronic Parkinsonism

in humans due to a product of meperidine-analog synthesis. Science 1983,

219, 979-980.

28. Crossman, A. R.; Clarke, C. E.; Boyce, S.; Robertson, R. G.; Sambrok, M.

A., MPTP-induced parkinsonism in the monkey: neurochemical pathology,

complications of treatment and pathophysiological mechanisms. Can J Neurol

Sci 1987, 14, 428-435.

29. Pifl, C.; Schingnitz, G.; Hornykievicz, O., The neurotoxin MPTP does not

reproduce in the rhesus monkey the interregional pattern of striatal dopamine

108

loss typical of human idiopathic Parkinson's disease. Neurosci Lett 1988, 92,

228-233.

30. Chiba, K.; Trevor, A.; Castagnoli, N. Jr., Metabolism of the neurotoxic

tertiary amine, MPTP, by brain monoamine oxidase. Biochem Biophys Res

Commun 1984, 120, 574-578.

31. Dimonte, D. A.; Wu, E.Y.; Delanney, L. E.; Irwin, I.; Langston, J.W.,

Toxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in primary cultures of

mouse astrocytes. J Pharmacol Exp Ther 1992, 261, 44-49.

32. Pifl, C.; Giros, B.; Caron, M. G., Dopamine transporter expression

confers cytotoxicity to low doses of the parkinsonism-inducing neurotoxin 1-

methyl-4-phenylpyridinium. J Neurosci 1993, 13, 4246-4253.

33. Peter, D.; Dimenez, J.; Liu, Y.; Kim, J.; Edwards, R. H., The chromaffin

granule and synaptic vesicle amine transporters differ in substrate recognition

and sensitivity to inhibitors. J Biol Chem 1994, 269, 7231-7237.

34. Lotharius, J.; O’Malley, K. L., The parkinsonism-inducing drug 1-methyl-

4-phenylpyridinium triggers intracellular dopamine oxidation. A novel

mechanism of toxicity. J Biol Chem 2000, 275, 38581-38588.

109

35. Nicklas,W. J.; Youngster, S. K.; Kindt, M. V.; Heikkila, R. E., MPTP,

MPP+ and mitochondrial function. Life Sci. 1987, 40, 721-729.

36. Nakamura, K.; Bindokas, V. P.; Marks, J. D.; Wright, D. A.; Frim, D. M.;

Miller, R. J.; Kang, U.J., The selective toxicity of 1-methyl-4-phenylpyridinium

to dopaminergic neurons: the role of mitochondrial complex I and reactive

oxygen species revisited. Mol Pharmacol 2000, 58, 271.

37. Waldmeier, P. C.; Boulton, A. A.; Cools, A. R.; Kato, A. C.; Tatton, W. G.,

Neurorescuing effects of the GAPDH ligand CGP 3466B. J Neural Transm Suppl.

2000, 60, 197-214.

38. Waldmeier, P. C.; Spooren, W. P.; Hengerer, B., CGP 3466 protects

dopaminergic neurons in lesion models of Parkinson's disease. Naunyn

Schmiedebergs Arch Pharmacol 2000, 362, 526-537.

39. Zimmermann, K.; Waldmeier, P.C., Tatton, W. G., Dibenzoxepines as

treatments for neurodegenerative diseases. Pure Appl Chem 1999, 71, 2039-

2046.

40. Langston, J. W.; Langston, E. B.; Irwin, I., MPTP-induced parkinsonism

in human and non-human primates--clinical and experimental aspects. Acta

Neurol. Scand. Suppl. 1984, 100, 49-54.

110

41. Ross, S. B.; Renyi, A.L., On the long-lasting inhibitory effect of N-(2-

chloroethyl)-N-ethyl-2-bromobenzylamine (DSP 4) on the active uptake of

noradrenaline. J Pharm Pharmacol 1976, 28, 458-459.

42. Finnegan, K. T.; Skratt, J. S.; Irwin, I.; DeLanney, L. E.; Langston, J. W.,

Protection against DSP-4-induced neurotoxicity by deprenyl is not related to its

inhibition of MAO B. Eur J Pharmacol 1990, 184, 119-126.

43. Ebadi, M.; Sharma, S.; Shavali, S.; El Refaey, H. J., Neuroprotective

actions of selegiline. Neurosci Res 2002, 67, 285-289.

44. Ricci, A.; Mancini, M.; Strocchi, P.; Bongrani, S.; Bronzetti, E., Deficits in

cholinergic neurotransmission markers induced by ethylcholine mustard

aziridinium (AF64A) in the rat hippocampus: sensitivity to treatment with the

monoamine oxidase-B inhibitor L-deprenyl. Drugs Exp Clin Res 1992, 18, 163-

171.

45. Youdim, M.B.; Bakhle, Y.S., Monoamine oxidase: isoforms and inhibitors

in Parkinson's disease and depressive illness. Br J Pharmacol 2006, 147, S287-

S296.

111

46. Yong, N.H.; Shi, Y. R.; Byung, H. H., Antioxidant Activity Resveratrol

Closely Correlates with Its Monoamine oxidase-A Inhibitory Activity. Arch

Pharm Res 1990, 13, 132-135.

47. Osman, F. Guner.; Douglas, R. Henry. Metric for Analyzing Hit Lists and

Pharmacophores. In Phamacophore Perception, Development, and Use in Drug

Design, Osman F. Guner., Ed.; International University Line: La Jolla,

California, 2000; pp 193-210.

48. Catalyst 4.11 User Guide, Accelrys Inc., San Diego, CA 92121, USA,

2005.

49. Debnath, A. K. Pharmacophore mapping of a series of 2,4-diamino-5-

deazapteridine inhibitors of Mycobacterium avium complex dihydrofolate

reductase. J. Med. Chem. 2002, 45, 41-53.

50. Kurogi, Y.; Güner, O. F. Pharmacophore modeling and three-

dimensionaldatabase searching for drug design using catalyst. Curr. Med.

Chem. 2001, 8,1035–1055.

51. Johnston, JP., Some observations upon a new inhibitor of

monoamineoxidase in brain tissue. Biochem Pharmacol 1968, 17, 1285–1297.

112

52. Shih, JC.; Chen, K.; Ridd, MJ., Monoamine oxidase: from genes

tobehavior. Annu Rev Neurosci 1999, 22, 197-217.

53. Fowler, JS.; Logan, J.; Wang, G.J.; Volkow, N.D.; Telang, F.; Zhu, W.;

Franceschi, D.; Pappas, N.; Ferrieri, R.; Shea, C.;, Garza, V.; Xu, Y.; Schlyer,

D.; Gatley, S.J.; Ding, Y.S.; Alexoff, D.; Warner, D.; Netusil, N.; Carter, P.;

Jayne, M.; King, P.; Vaska, P., Low monoamine oxidase B in peripheral organs

in smokers. Proc Natl Acad Sci U S A. 2003, 100 (20), 11600-11605.

54. Kumar, M.J.; Nicholls, D.G.; Andersen, J.K., Oxidative alpha-

ketoglutarate dehydrogenase inhibition via subtle elevations in monoamine

oxidase B levels results in loss of spare respiratory capacity: implications for

Parkinson's disease. J Biol Chem 2003, 278 (47), 46432-46439.

55. Trendelenburg, U.; Weiner, N., Monoamine Oxidase, in: M.B.H. Youdim,

J.P.M. Finberg, K.F. Tipton (Eds.), Advances in Experimental Pharmacology,

Springer-Verlag, Berlin, 1988, 119–192.

56. Knoll, J.; Magyar, K., Some puzzling pharmacological effects of

monoamine oxidase inhibitors. Adv Biochem Psychopharmacol. 1972, 5, 393-

408.

113

57. Bohm, H.J.; Flohr, A.; Stahl, M., Scaffold hopping, Drug Discov Today

Technol, 2004, 1, 217–224.

58. Zhao, H., Scaffold selection and scaffold hopping in lead generation: a

medicinal chemistry perspective. Drug Discov Today, 2007, 12, 149–155.

59. Ertl, P.;, Jelfs, S.; Mühlbacher, J.; Schuffenhauer, A.; Selzer, P., Quest

for the rings. In silico exploration of ring universe to identify novel bioactive

heteroaromatic scaffolds, J Med Chem, 2006, 49, 4568-4573.

60. Gritsch, S.; Guccione, S.; Hoffmann, R.; Cambria, A.; Raciti, G.; Langer,

T., 3D QSAR study of monoamino oxidase-B inhibitors using the chemical

function based pharmacophore generation approach, J Enzyme Inhib, 2001,

16, 199–215.

61. Maestro, Version 1.0.9113, Schrodinger, L.L.C., New York, 2006.

62. Glide, Version 3.5, Schrodinger, L.L.C., New York, 2006.

63. Cerius2, Version 4.11, Accelrys Inc., San Diego, CA 92121, USA, 2007.

64. Catalyst, Version 4.11, Accelrys Inc., San Diego, CA 92121, USA, 2007.

114

65. Nesrin, G.; Akgul, Y.S.; Gulberk, U.; Kevser, E.; Altan, A.B., 1-N-

Substituted Thiocarbamoyl-3-phenyl-5-thienyl-2-pyrazolines: Synthesis and

Evaluation as MAO Inhibitors, Arch Pharm Pharm Med Chem, 2003, 336, 362–

371.

66. Herraiz, T.; Chaparro, C., Human monoamine oxidase is inhibited by

tobacco smoke: beta-carboline alkaloids act as potent and reversible inhibitors.

Biochem Biophys Res Commun, 2005, 326, 378–386.

67. Yáñez, M.; Fraiz, N.; Cano, E.; Orallo, F., Inhibitory effects of cis- and

trans-resveratrol on noradrenaline and 5-hydroxytryptamine uptake and on

monoamine oxidase activity, Biochem Biophys Res Commun, 2006, 344, 688–

695.

68. Tao, G.; Irie, Y.; Li, D.J.; Keung, W.M., Eugenol and its structural

analogs inhibit monoamine oxidase A and exhibit antidepressant-like activity,

Bioorg Med Chem, 2005, 13, 4777–4788.

69. Chimenti, F.; Bolasco, A.; Manna, F.; Secci, D.; Chimenti, P.; Granese,

A.; Befani, O.; Turini, P.; Alcaro, S.; Ortuso, F., Synthesis and molecular

modelling of novel substituted-4,5-dihydro-(1H)-pyrazole derivatives as potent

and highly selective monoamine oxidase-A inhibitors, Chem Biol Drug Des,

2006, 67, 206–214.

115

70. Hutchinson, D.K., Oxazolidinone antibacterial agents: a critical review,

Curr Top Med Chem, 2003, 3, 1021–1042.

71. Rosen, T.C.; Yoshida, S.; Fröhlich, R.; Kirk, K.L.; Haufe, G., Fluorinated

phenylcyclopropylamines. 2. Effects of aromatic ring substitution and of

absolute configuration on inhibition of microbial tyramine oxidase, J Med

Chem, 2004, 47, 5860–5871.

72. Hubálek, F.; Binda, C.; Li, M.; Herzig, Y.; Sterling, J.; Youdim, M.B.;

Mattevi, A.; Edmondson, DE., Inactivation of purified human recombinant

monoamine oxidases A and B by rasagiline and its analogues, J Med Chem,

2004, 47, 1760–1766.

73. Wang, E.Y.; Gao, H.; Salter, C.L.; Zhang, J.; Huang, L.; Podar, E.M.;

Miller, A.; Zhao, J.; O'rourke, A.; Linnik, M.D., J Med Chem, 2006, 49, 2166–

2173.

74. Debnath, A.K., Pharmacophore mapping of a series of 2,4-diamino-5-

deazapteridine inhibitors of Mycobacterium avium complex dihydrofolate

reductase, J Med Chem, 2002, 45, 41–53.

116

75. Vadivelan, S.; Sinha, B.N.; Irudayam, S.J.; Jagarlapudi, S.A., Virtual

screening studies to design potent CDK2-cyclin A inhibitors, J Chem Inf Model,

2007, 47, 1526–1535.

76. Vadivelan, S.; Sinha, B.N.; Rambabu, G.; Boppana, K.; Jagarlapudi, S.A.,

Pharmacophore modeling and virtual screening studies to design some

potential histone deacetylase inhibitors as new leads, J Mol Graph Model, 2008,

26, 935–946.

77. Vadivelan, S.; Sinha, B.N.; Sunita, T.; Sarma, J.A.R.P., Fragment and

knowledge-based design of selective GSK-3ß inhibitors using virtual screening

models, Eur J Med Chem, 2009, 44, 2361-2371.

78. Guner, O.F.; Henry, D.R.; Phamacophore Perception, Development, and

Use in Drug Design, Osman F. Guner (Ed.), International University Line, La

Jolla, California, 2000, 193–210.

79. Berman, H. M.; Bhat, T. N.; Bourne, P. E.; Feng, Z.; Gilliland, G.;

Weissig, H.; Westbrook, J. The Protein Data Bank and the challenge of

structural genomics. Nature Struct. Biol. 2000, 7, 957–959.

80. Westbrook, J.; Feng, Z.; Chen, L.; Yang, H.; Berman, H. M. The Protein

Data Bank and structural genomics. Nucleic Acid Res. 2003, 31, 489–491.

117

81 Blundell, TL.; Jhoti, H.; Abell, C. High-throughput crystallography for

lead discovery in drug design. Nature Rev. Drug Discov. 2002, 1, 45–54.

82 Chen, H.; Lyne, P. D.; Giordanetto, F.; Lovell, T.; Li, J. On evaluating

molecular-docking methods for pose prediction and enrichment factors. J.

Chem. Inf. Model. 2006, 46, 401-415.

83. Bissantz, C.; Folkers, G.; Rognan, D. Protein-based virtual screening of

chemical databases. 1. Evaluation of different docking/scoring combinations.

J. Med. Chem. 2000, 43, 4759-4767.

84. Glen, R. C.; Allen, S. C. Ligand-protein docking: cancer research at the

interface between biology and chemistry. Curr. Med. Chem. 2003, 10, 763-777.

85. Kitchen, D. B.; Decornez, H.; Furr, J. R.; Bajorath, J. Docking and

scoring in virtual screening for drug discovery: methods and applications. Nat.

Rev. Drug Discovery, 2004, 3, 935-949.

86. Ingo, Muegge.; Istvan, J. Enyedy. Virtual Screening of Kinase Targets.

Curr. Med. Chem. 2004, 11, 693-707.

118

87. Berman, H. M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T. N.;

Weissig, H.; Shindyalov I. N.; Bourne P. E. The Protein Data Bank. Nucleic

Acids Res. 2000, 28, 235-242.

88. Gohlke, H.; Klebe, G. Statistical potentials and scoring functions applied

to protein-ligand binding. Curr. Opin. Struct. Biol. 2001, 11, 231–235.

89. Marcel, L. Verdonk.; Jason, C. Cole.; Michael, J. Hartshorn.;

Christopher, W. Murray.; Richard, D. Taylor. Improved protein-ligand docking

using GOLD. Proteins: Structure, Function, and Genetics 2003, 52, 609–623.

90. Bartosz, A. Grzybowski.; Alexey, V. Ishchenko.; Chu-Young Kim.; George

Topalov.; Robert Chapman.; David, W. Christianson.; George, M. Whitesides.;

Eugene, I. Shakhnovich. Combinatorial computational method gives new

picomolar ligands for a known enzyme. J. Comput.-Aided Mol. Des., 1997, 11,

425-445.

91. Baxter, C. A.; Murray, C. W.; Clark, D. E.; Westhead D. R.; Eldridge, M.

D. Flexible Docking Using Tabu Search and an Empirical Estimate of Binding

Affinity. Proteins, 1998, 33, 367-382.

92. Glide, version 3.5; Schrodinger, L.L.C., New York, 2006.

119

93. Friesner, R. A.; Banks, J. L.; Murphy, R. B.; Halgren, T. A.; Klicic, J. J.;

Mainz, D. T.; Repasky, M. P.; Knoll, E. H.; Shelley, M.; Perry, J. K.; Shaw, D.

E.; Francis, P.; Shenkin, P. S. Glide: a new approach for rapid, accurate

docking and scoring. 1. Method and assessment of docking accuracy. J. Med.

Chem. 2004, 47, 1739-1749.

94. Halgren, T. A.; Murphy, R. B.; Friesner, R. A.; Beard, H. S.; Frye, L. L.;

Pollard, W. T.; Banks, J. L. Glide: a new approach for rapid, accurate docking

and scoring. 2. Enrichment factors in database screening. J. Med. Chem. 2004,

47, 1750-1759.

95. Cerius2 4.11 User Guide, Accelrys Inc., San Diego, CA 92121, USA,

2005.

96. Hodgson, J., ADMET--turning chemicals into drugs. Nat Biotechnol

2001, 19, (8), 722-6

97. Binda, C.; Wang, J.; Pisani, L.; Caccia, C.; Carotti, A.; Salvati, P.;

Edmondson, D.E.; Mattevi, A., Structures of human monoamine oxidase B

complexes with selective noncovalent inhibitors: safinamide and coumarin

analogs, J Med Chem, 2007, 50, 5848–5852.

120

98. Berman, H.M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T.N.; Weissig,

H.; Shindyalov, I.N.; Bourne, P.E., The Protein Data Bank, Nucleic Acids Res,

2000, 28, 235–242.

99. Barros, A. I. R. N. A.; Silva, A. M. S.; Alkorta, I.; Elguero, J. Synthesis,

experimental and theoretical NMR study of 2’-hydroxychalcones bearing a nitro

substituent on their B ring, Tetrahedron, 2004, 60, 6513-6521.

100. Sharma, T. C.; Saksena, V.; Reddy, N. J., Oxidation of some

hydroxyarylpyrazolines with manganese dioxide, Acta Chim. Acad. Sci. Hungar.,

1977, 93, 415-419.

101. Gokhan, N.; Yesilada, A.; Ucar, G.; Erol, K.; Bilgin, A. A., 1-N-Substituted

Thiocarbamoyl-3-phenyl-5-thienyl-2-pyrazolines: Synthesis and Evaluation as

MAO Inhibitors, Arch. Pharm. (Weinheim, Ger.) 2003, 336, 362-371.

102. Holt, A.; Sharman, D. F.; Baker, G. B.; Palcic, M. M., A continuous

spectrophotometric assay for Monoamine Oxidase and related enzymes in

tissue homogenates, Anal. Biochem. 1997, 244, 384-392.

103. Bradford, M. M. A, rapid and sensitive method for the quantitation of

microgram quantities of protein utilizing the principle of Protein-Dye Binding,

Anal. Biochem. 1976, 72, 248-254.